Azelastine and olopatadine in the treatment of allergic rhinitis

Annals of Allergy, Asthma and Immunology

Volumn 103, Issue 5, 2009, Pages 373-380

  Kaliner, Michael A ^a  

^a Institute for Asthma and Allergy   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; ASTEPRO; AZELASTINE; BECLOMETASONE; CETIRIZINE; CHLORPHENIRAMINE; DESLORATADINE; FEXOFENADINE; FLUTICASONE; FLUTICASONE PROPIONATE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LORATADINE; NOSE SPRAY; OLOPATADINE; PLACEBO; STEROID; UNCLASSIFIED DRUG; ANTIALLERGIC AGENT; DIBENZOXEPIN DERIVATIVE; PHTHALAZINE DERIVATIVE;

ALLERGIC RHINITIS; BITTER TASTE; CHRONIC RHINITIS; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENVIRONMENTAL EXPOSURE; EPISTAXIS; HEADACHE; HUMAN; IMMUNOTHERAPY; MEDICAL LITERATURE; MONOTHERAPY; NASAL PRURITUS; NOSE CONGESTION; NOSE DISEASE; PEER REVIEW; POLLEN; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SEASONAL VARIATION; SIDE EFFECT; SNEEZING; SOMNOLENCE; SORE THROAT; UNITED STATES; UNSPECIFIED SIDE EFFECT; VASOMOTOR RHINITIS; HAY FEVER; INTRANASAL DRUG ADMINISTRATION; PERENNIAL RHINITIS; TREATMENT OUTCOME;

ADMINISTRATION, INTRANASAL; ANTI-ALLERGIC AGENTS; CLINICAL TRIALS AS TOPIC; DIBENZOXEPINS; HUMANS; PHTHALAZINES; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL; TREATMENT OUTCOME;

EID: 73349092155     PISSN: 10811206     EISSN: 15344436     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)60355-9     Document Type: Review

References (57)

1. Wallace DV, Dykewicz MS, Bernstein DI, et al. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol. 2008;122(2 suppl):S1-S84.
2. Agency for Healthcare Research and Quality. Management of Allergic Rhinitis in the Working-Age Population: Evidence Report/Technology Assessment No. 67. Washington, DC: Agency for Healthcare Research and Quality; January 2003. Publication 03-E013.
3. Settipane RA. Rhinitis: a dose of epidemiological reality. Allergy Asthma Proc. 2003;24:147-154.
4. Bousquet J, van Cauwenberge PB, Khaltaev N, et al. Allergic rhinitis and its impact on asthma: ARIA workshop report. J Allergy Clin Immunol. 2001;108:S147.
5. Naclerio RM. Allergic rhinitis. N Engl J Med. 1991;325:860-869.
6. Hofstra CL, Desai PJ, Thurmond RL, Fung-Leung WP. Histamine H4 receptor mediates chemotaxis and calcium mobilization of mast cells. J Pharmacol Exp Ther. 2003;305:1212-1221.
7. Ray NF, Baraniuk JN, Thamer M, et al. Direct expenditures for the treatment of allergic rhinoconjunctivitis in 1996, including the contributions of related airway illnesses. J Allergy Clin Immunol. 1999;103: 401-407.
8. Ross RN. The costs of allergic rhinitis. Am J Manag Care. 1996;2: 285-290.
9. Lamb CE, Ratner PH, Johnson CE, et al. Economic impact of workplace productivity losses due to allergic rhinitis compared with select medical conditions in the United States from an employer perspective. Curr Med Res Opin. 2006;22:1203-1210.
10. Kaliner MA. The treatment of vasomotor nonallergic rhinitis. Clin Allergy Immunol. 2007;19:351-362.
11. Kaliner MA, Baraniuk JN, Benninger M, et al. Consensus definition of nonallergic rhinopathy (NAR), previously referred to as vasomotor rhinitis (VMR), nonallergic rhinitis, and/or idiopathic rhinitis. J World Allergy Org. 2009;2:119 -120.
12. ASTELIN® (azelastine hydrochloride) Nasal Spray, 137 mcg [prescribing information]. Somerset, NJ: MedPointe Healthcare; 2006.
13. Patanase® (olopatadine hydrochloride) 665 mcg Nasal Spray [prescribing information]. Fort Worth, TX: Alcon Laboratories; 2009.
14. Bernstein JA. Azelastine hydrochloride: a review of pharmacology, pharmacokinetics, clinical efficacy and tolerability. Curr Med Res Opin. 2007;23:2441-2452.
15. Casale TB. The interaction of azelastine with human lung histamine H1, beta, and muscarinic receptor-binding sites. J Allergy Clin Immunol. 1989;83:771-776.
16. Lieberman PL, Settipane RA. Azelastine nasal spray: a review of pharmacology and clinical efficacy in allergic and nonallergic rhinitis. Allergy Asthma Proc. 2003;24:95-105.
17. Weiler JM, Meltzer EO, Benson PM, et al. A dose-ranging study of the efficacy and safety of azelastine nasal spray in the treatment of seasonal allergic rhinitis with an acute model. J Allergy Clin Immunol. 1994;94: 972-980.
18. Horak F, Zieglmayer UP, Zieglmayer R, et al. Azelastine nasal spray and desloratadine tablets in pollen-induced seasonal allergic rhinitis: a pharmacodynamic study of onset of action and efficacy. Curr Med Res Opin. 2006;22:151-157.
19. Patel P, D'Andrea C, Sacks H. Onset of action of azelastine nasal spray compared with mometasone nasal spray and placebo in subjects with seasonal allergic rhinitis evaluated in an environmental exposure chamber. Am J Rhinol. 2007;21:499 -503.
20. Meltzer EO, Weiler JM, Dockhorn RJ, et al. Azelastine nasal spray in the management of seasonal allergic rhinitis. Ann Allergy. 1994;72: 354-359.
21. Storms WW, Pearlman DS, Chervinsky P, et al. Effectiveness of azelastine nasal solution in seasonal allergic rhinitis. Ear Nose Throat J. 1994;73:382-394.
22. Ratner PH, Findlay SR, Hampel F, et al. A double-blind, controlled trial to assess the safety and efficacy of azelastine nasal spray in seasonal allergic rhinitis. J Allergy Clin Immunol. 1994;94:818-825.
23. LaForce C, Dockhorn RJ, Prenner BM, et al. Safety and efficacy of azelastine nasal spray (Astelin NS) for seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 1996;76:181-188.
24. Lumry W, Prenner B, Corren J, Wheeler W. Efficacy and safety of azelastine nasal spray at a dosage of one spray per nostril twice daily. Ann Allergy Asthma Immunol. 2007;99:267-272.
25. Berger WE. Pharmacokinetic characteristics and safety and tolerability of a reformulated azelastine hydrochloride nasal spray in patients with chronic rhinitis. Expert Opin Drug Metab Toxicol. 2009;5:91-102.
26. Sacks H. Sensory study of a new formulation of azelastine nasal spray with reduced bitterness. Poster presented at: 2009 Annual Meeting of the Western Society for Allergy, Asthma, and Immunology; January 25-29, 2009; Wailea, Maui, Hawaii.
27. Banov CH, Lieberman P. Efficacy of azelastine nasal spray in the treatment of vasomotor (perennial nonallergic) rhinitis. Ann Allergy Asthma Immunol. 2001;86:28 -35.
28. ASTEPRO™ (azelastine hydrochloride) Nasal Spray [prescribing information]. Somerset, NJ: MEDA Pharmaceuticals; 2008.
29. Yanni JM, Stephens DJ, Miller ST, et al. The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/ antihistaminic agent. J Ocul Pharmacol Ther. 1996;12:389-400.
30. Pipkorn P, Costantini C, Reynolds C, et al. The effects of the nasal antihistamines olopatadine and azelastine in nasal allergen provocation. Ann Allergy Asthma Immunol. 2008;101:82- 89.
31. Patel D, Garadi R, Brubaker M, et al. Onset and duration of action of nasal sprays in seasonal allergic rhinitis patients: olopatadine hydrochloride versus mometasone furoate monohydrate. Allergy Asthma Proc. 2007;28:592-599.
32. Patel D, Wall M, Brubaker M, et al. Olopatadine nasal spray 0.6% vs placebo and mometasone in treating seasonal allergic rhinitis in an environmental exposure chamber. Allergy Asthma Proc. In press.
33. Meltzer EO, Hampel FC, Ratner PH, et al. Safety and efficacy of olopatadine hydrochloride nasal spray for the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2005;95:600-606.
34. Ratner PH, Hampel FC, Amar NJ, et al. Safety and efficacy of olopatadine hydrochloride nasal spray for the treatment of seasonal allergic rhinitis to mountain cedar. Ann Allergy Asthma Immunol. 2005;95: 474-479.
35. Fairchild CJ, Meltzer EO, Roland PS, Wells D, Drake M, Wall GM. Comprehensive report of the efficacy, safety, quality of life, and work impact of olopatadine 0.6% and olopatadine 0.4% treatment in patients with seasonal allergic rhinitis. Allergy Asthma Proc. 2007;28:716 -723.
36. Hampel FC Jr, Ratner PH, Amar NJ, et al. Improved quality of life among seasonal allergic rhinitis patients treated with olopatadine HCL nasal spray 0.4% and olopatadine HCl nasal spray 0.6% compared with vehicle placebo. Allergy Asthma Proc. 2006;27:202-207.
37. Shah SR, Nayak A, Ratner P, Roland P, Michael Wall G. Effects of olopatadine hydrochloride nasal spray 0.6% in the treatment of seasonal allergic rhinitis: a phase III, multicenter, randomized, double-blind, active- and placebo-controlled study in adolescents and adults. Clin Ther. 2009;31:99 -107.
38. Kaliner MA. A novel and effective approach to treating rhinitis with nasal antihistamines. Ann Allergy Asthma Immunol. 2007;99:383-391.
39. Berger WE, White MV; Rhinitis Study Group. Efficacy of azelastine nasal spray in patients with an unsatisfactory response to loratadine. Ann Allergy Asthma Immunol. 2003;91:2005-2011.
40. LaForce CF, Corren J, Wheeler WJ, et al. Efficacy of azelastine nasal spray in seasonal allergic rhinitis patients who remain symptomatic after treatment with fexofenadine. Ann Allergy Asthma Immunol. 2004;93: 154-159.
41. Corren J, Storms WW, Bernstein J, et al. Effectiveness of azelastine nasal spray compared to oral cetirizine in patients with seasonal allergic rhinitis. Clin Ther. 2005;27:543-553.
42. Berger W, Hampel F, Bernstein J, et al. Impact of azelastine nasal spray on symptoms and quality of life compared with cetirizine oral tablets in patents with seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2006;97:375-381.
43. Lee TA, Pickard S. Meta-analysis of azelastine nasal spray for the treatment of allergic rhinitis. Pharmacotherapy. 2007;27:852- 859.
44. Berger WE, Fineman SM, Lieberman P, Mile RM; Rhinitis Study Groups. Double-blind trials of azelastine nasal spray monotherapy versus combination therapy with loratadine tablets and beclomethasone nasal spray in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 1999;82:535-541.
45. Yanez A, Rodrigo GJ. Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis: a systematic review with meta-analysis. Ann Allergy Asthma Immunol. 2002;89: 479-484.
46. Kaliner MA, Storms W, Tilles S, et al. Comparison of olopatadine 0.6% nasal spray versus fluticasone propionate 50 mcg in the treatment of seasonal allergic rhinitis. Allergy Asthma Proc. 2009;30:255-262.
47. Ratner P, Hampel F, Van Bavel J, et al. Combination therapy with azelastine hydrochloride nasal spray and fluticasone propionate nasal spray in the treatment of patients with seasonal allergic rhinitis. 2008; 100:74-81.
48. Juniper EF, Kline PA, Hargreave FE. Dolovich J. Comparison of beclomethasone dipropionate aqueous nasal spray, astemizole, and the combination in the prophylactic treatment of ragweed pollen-induced rhinoconjunctivitis. J Allergy Clin Immunol. 1989;83:627- 633.
49. Ratner PH, van Bavel JH, Martin BG, et al. A comparison of the efficacy of fluticasone propionate aqueous nasal spray and loratadine, alone and in combination, for the treatment of seasonal allergic rhinitis. J Fam Pract. 1998;47:118 -125.
50. Simpson RJ. Budesonide and terfenadine, separately and in combination, in the treatment of hay fever. Ann Allergy. 1994;73:497-502.
51. Backhouse CI, Finnamore VP, Gosden CW. Treatment of seasonal allergic rhinitis with flunisolide and terfenadine. J Internat Med Res. 1986;14:35- 41.
52. Juniper EF, Guyatt GH, Ferrie PJ, Griffith LE. First-line treatment of seasonal (ragweed) rhinoconjunctivitis: a randomized management trial comparing a nasal steroid spray and a nonsedating antihistamine. CMAJ. 1997;156:1123-1131.
53. Barnes ML, Ward JH, Fardon TC, Lipworth BJ. Effects of levocetirizine as add-on therapy to fluticasone in seasonal allergic rhinitis. Clin Exp Allergy. 2006;36:676-684.
54. di Lorenzo G, Pacor ML, Pellitteri MF, et al. Randomized placebo-controlled trial comparing fluticasone aqueous nasal spray in monotherapy, fluticasone plus cetirizine, fluticasone plus montelukast and cetirizine plus montelukast for seasonal allergic rhinitis. Clin Exp Allergy. 2004;34:259 -267.
55. Hampel F, Ratner P, Diaz J, Sacks H. Efficacy and safety of azelastine hydrocloride [sic] and fluticasone propionate combined in a single nasal spray delivery device in patients with seasonal allergic rhinitis. J Allergy Clin Immunol. 2009;123:S155.
56. Berkowitz R, Braker S, Fredane L, Sacks H. Onset of action and pharmacokinetic parameters of azelastine hydrochloride in azelastine nasal spray and in a combination nasal spray with fluticasone propionate. J Allergy Clin Immunol. 2009;123:S131.
57. Salapatek A, Angelo PD, Bates M, et al. Novel combination product captisol-enabled® budesonide + azelastine HCl provides fast, long-lasting relief of allergic rhinitis symptoms (total nasal symptom score (TNSS) and individual nasal symptoms scores (NSS) in ragweed allergic patients studied in an environmental exposure chamber (EEC) model. J Allergy Clin Immunol. 2009;123:S130.